Other languages Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
3.11 ^USD	+0.65%		-14.56%	-45.72%

May. 09	Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating	MT
May. 07	Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	Apr. 05
Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients	Apr. 04
Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	Apr. 04
50 valores para invertir en IA, salud, movilidad y energía	Mar. 25
50 aandelen om te beleggen in KI, gezondheid, mobiliteit en energie	Mar. 23
50 titoli per investire in AI, salute, mobilità ed energia	Mar. 22
50 Top-Aktien für Investitionen in KI, Gesundheit, Mobilität und Energie	Mar. 22
50 valeurs pour investir dans l'IA, la Santé, la Mobilité et l'Energie	Mar. 22
Caribou Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 11
Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer	Jan. 07
Caribou Biosciences Says it Reached Alignment With FDA on Phase 3 Trial Plan for Lymphoma Treatment	Dec. 13
MORNING BRIEFING - USA/Asien	Dec. 13
Syed Rizvi to Leave the Caribou Biosciences, Inc. as Chief Medical Officer, Effective from December 31, 2023	Dec. 12
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024	Dec. 12
Caribou Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Caribou Biosciences, Inc. Appoints Sundar Jagannath to its Scientific Advisory Board	Nov. 06
US FDA Clears Caribou Biosciences' CB-012 Cancer Drug Candidate for Human Study	23-10-18
Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	23-10-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Other languages

Filters